RxDoctor Payments Data

Nika Omid, MD

Ophthalmology · Irvine, CANPI 1346425964

Payments from drug & device makers

$1,567in general payments, 2019–2025

Across 13 payments — averaging $120.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$762
  • NEW World Medical,inc.$283
  • Bausch & Lomb Americas Inc.$125
  • Rxsight Inc$122
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$99
  • AbbVie$82
  • plus $94 from 3 others

What the payments were for

  • Travel & lodging$44228%
  • Food & beverage$1,12572%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,567 in reported general payments places this provider in the 50th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$105,761
Medicare patients
269
Services billed
771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine138$185,303
Cyclosporine159$98,015
XiidraLifitegrast30$36,833
LumiganBimatoprost35$20,149
ProlensaBromfenac Sodium39$15,122
CombiganBrimonidine Tartrate/Timolol32$12,632
VyzultaLatanoprostene Bunod25$11,853
Prednisolone Acetate105$2,510
Latanoprost191$2,319
MoxifloxacinMoxifloxacin Hcl105$2,238
Brimonidine Tartrate17$1,891
Tobramycin-DexamethasoneTobramycin/Dexamethasone60$1,706
ErythromycinErythromycin Base167$1,662
Azelastine Hcl103$1,593
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat58$1,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$82$218,084205 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$125$48,68655 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$99$15,12239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →